Compare Stocks: PLRZ, VRCA, FBIO, and ICCC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.72 +0.4%	$3.03	$2.18 ▼ $4.53	$90.38M	1.19	562,632 shs	168,115 shs
ICCC ImmuCell	$9.90 -1.0%	$10.59	$4.52 ▼ $12.10	$90.82M	0.54	30,783 shs	11,695 shs
PLRZ Polyrizon	$11.24 -10.5%	$12.46	$2.88 ▼ $18.20	$23.42M	-1.39	81,071 shs	141,280 shs
VRCA Verrica Pharmaceuticals	$5.30 -1.1%	$5.46	$3.28 ▼ $9.82	$92.08M	1.49	113,170 shs	12,187 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+0.37%	-1.81%	-2.51%	+2.64%	-7.80%
ICCC ImmuCell	-1.00%	-0.40%	-7.91%	+3.02%	+56.27%
PLRZ Polyrizon	-10.51%	-14.52%	-0.09%	-13.47%	+78.41%
VRCA Verrica Pharmaceuticals	-1.12%	-6.85%	-3.81%	-12.25%	+1.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.72 +0.4%	$3.03	$2.18 ▼ $4.53	$90.38M	1.19	562,632 shs	168,115 shs
ICCC ImmuCell	$9.90 -1.0%	$10.59	$4.52 ▼ $12.10	$90.82M	0.54	30,783 shs	11,695 shs
PLRZ Polyrizon	$11.24 -10.5%	$12.46	$2.88 ▼ $18.20	$23.42M	-1.39	81,071 shs	141,280 shs
VRCA Verrica Pharmaceuticals	$5.30 -1.1%	$5.46	$3.28 ▼ $9.82	$92.08M	1.49	113,170 shs	12,187 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+0.37%	-1.81%	-2.51%	+2.64%	-7.80%
ICCC ImmuCell	-1.00%	-0.40%	-7.91%	+3.02%	+56.27%
PLRZ Polyrizon	-10.51%	-14.52%	-0.09%	-13.47%	+78.41%
VRCA Verrica Pharmaceuticals	-1.12%	-6.85%	-3.81%	-12.25%	+1.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	2.25	Hold	$17.00	525.00% Upside
ICCC ImmuCell	2.00	Hold	N/A	N/A
PLRZ Polyrizon	1.00	Sell	N/A	N/A
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	138.99% Upside

Current Analyst Ratings Breakdown

Latest PLRZ, VRCA, FBIO, and ICCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	VRCA Verrica Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/14/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$63.26M	1.43	N/A	N/A	$6.18 per share	0.44
ICCC ImmuCell	$27.64M	3.25	$0.19 per share	51.87	$3.45 per share	2.87
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A
VRCA Verrica Pharmaceuticals	$30.32M	3.00	N/A	N/A	$0.25 per share	21.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	$6.82M	$2.64	1.03	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	123.77	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest PLRZ, VRCA, FBIO, and ICCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	0.17	3.96	3.83
ICCC ImmuCell	0.22	4.75	2.71
PLRZ Polyrizon	N/A	29.03	29.03
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
ICCC ImmuCell	13.47%
PLRZ Polyrizon	N/A
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	28.50%
ICCC ImmuCell	5.70%
PLRZ Polyrizon	N/A
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	33.35 million	23.85 million	Optionable
ICCC ImmuCell	70	9.08 million	8.56 million	Not Optionable
PLRZ Polyrizon	N/A	2.08 million	N/A	N/A
VRCA Verrica Pharmaceuticals	40	17.18 million	8.09 million	No Data

PLRZ, VRCA, FBIO, and ICCC Headlines

Recent News About These Companies

Verrica Pharmaceuticals (NASDAQ:VRCA) Coverage Initiated at Lake Street Capital

August 29, 2026 | americanbankingnews.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Lake Street Capital Begins Coverage on Verrica Pharmaceuticals (NASDAQ:VRCA)

August 27, 2026 | marketbeat.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Brokerages

August 25, 2026 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

August 20, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

August 18, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

August 18, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

August 15, 2026 | marketbeat.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results

August 6, 2026 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, VRCA, FBIO, and ICCC Company Descriptions

Fortress Biotech NASDAQ:FBIO

$2.72 +0.01 (+0.37%)

As of 09/4/2026 04:00 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmuCell NASDAQ:ICCC

$9.90 -0.10 (-1.00%)

As of 09/4/2026 04:00 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Polyrizon NASDAQ:PLRZ

$11.24 -1.32 (-10.51%)

As of 09/4/2026 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.30 -0.06 (-1.12%)

As of 09/4/2026 04:00 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRZ, VRCA, FBIO, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRZ, VRCA, FBIO, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRZ, VRCA, FBIO, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, VRCA, FBIO, and ICCC Company Descriptions

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

Polyrizon NASDAQ:PLRZ

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRZ, VRCA, FBIO, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRZ, VRCA, FBIO, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRZ, VRCA, FBIO, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, VRCA, FBIO, and ICCC Company Descriptions

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

Polyrizon NASDAQ:PLRZ

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools